Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
Clinical trial NCT03041311 · COMPLETED
Trial details
- NCT number
- NCT03041311
- Sponsor
- G1 Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-29
- Primary completion
- 2018-08-17
- Enrollment
- 107
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.